HDAC10 and primary cutaneous T-cell non-Hodgkin lymphoma: The cytotoxic effect of a novel, specific to HDAC10 inhibitor (DKFZ-748) (Steimbach et al., 2022) was tested in CTCL cell lines and primary cells from CTCL patients, including SS2, MF1, and MF2 and in healthy donors (HD1-4).